We further evaluated the antiproliferative effects of quizartinib using native blasts isolated from patients with newly diagnosed FLT3- or KIT-activated AML (additional patient characteristics are provided in Additional file 2: Table S1 with the online version of the article). The gene discussed is KIT; the disease is acute myeloid leukemia.